H.C. Wainwright lowered the firm’s price target on Sage Therapeutics to $27 from $50 and keeps a Neutral rating on the shares. For Zuranolone in major major depressive disorder, the analyst assigns a probability of success of 50%, saying additional studies will be necessary to support approvability as well as the mixed results obtained across the developmental program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SAGE:
- Sage Therapeutics downgraded to Hold from Buy at Canaccord
- Biogen price target lowered to $294 from $311 at Barclays
- Cantor Fitzgerald bullish on Axsome after Q2 results, Sage’s zuranolone CRL
- Sage Therapeutics downgraded to Neutral at BofA after MDD CRL
- Sage Therapeutics downgraded to Neutral from Buy at BofA